Overview

Digestive health is a critical aspect of overall well-being, and its optimization can significantly improve patients' quality of life. iollo's advanced metabolomic testing offers healthcare providers a powerful tool to identify imbalances in gut function and microbiome health, enabling the development of personalized interventions for their patients.

This educational material aims to familiarize physicians with the key digestive health markers measured by iollo's test, their interpretation, and the potential benefits for patients experiencing various gastrointestinal issues.

‍

Who May Benefit from This Test?

iollo's digestive health testing can be particularly beneficial for patients experiencing various symptoms or conditions related to gut dysfunction. Some of the key indications for testing include:

1. Bloating, gas, or abdominal pain: Patients with persistent digestive discomfort may have underlying imbalances in gut bacteria or intestinal function contributing to their symptoms.
2. Diarrhea or constipation: Chronic or recurrent bowel movement irregularities can be indicative of gut dysbiosis or altered bile acid metabolism.
3. Acid reflux or heartburn: Patients with frequent acid reflux or gastroesophageal reflux disease (GERD) may benefit from metabolomic testing to identify potential contributing factors.
4. Irritable bowel syndrome (IBS): Individuals diagnosed with IBS can gain insights into their gut microbiome composition and metabolic markers associated with symptom severity.
5. Inflammatory bowel disease (IBD): Patients with IBD, such as Crohn's disease or ulcerative colitis, can benefit from monitoring gut-derived metabolites that may contribute to inflammation and disease activity.

Other patients who may benefit from digestive health testing include those with a history of antibiotic use, individuals with food intolerances or allergies, and those experiencing systemic symptoms related to gut health, such as fatigue or skin issues.

‍

Understanding Digestive Health Markers

iollo's Digestive Health Panel measures a comprehensive set of biomarkers that provide insights into various aspects of gut function and microbiome health.

Some of the key markers include:

1. Indolepropionic Acid (IPA): This beneficial metabolite produced by gut bacteria has neuroprotective and antioxidant effects. Low levels have been linked to an imbalance in the gut microbiome and an increased risk of cardiovascular, metabolic, and neurodegenerative diseases [1,2,3,4].
2. Glutamine: This amino acid is essential for maintaining the integrity of the intestinal lining and supporting immune function. Low levels have been associated with damage to the gut barrier and the development of inflammatory bowel syndrome and leaky gut syndrome [5,6].
3. p-Cresol Sulfate and Indoxyl Sulfate: These uremic toxins are produced by specific gut bacteria and can contribute to inflammation and oxidative stress. High levels have been linked to kidney damage and an increased risk of cardiovascular and metabolic diseases [7,8,9].
4. Deoxycholic Acid (DCA): This secondary bile acid is associated with an increased risk of colorectal cancer. High levels may indicate altered bile acid metabolism and prolonged stool transit time [10,11].

‍

Interpreting Results and Patient Benefits

iollo's metabolomic testing provides valuable insights into patients' digestive health status:

• Identifying imbalances in key gut-derived metabolites can reveal underlying issues such as gut dysbiosis, intestinal permeability, or altered bile acid metabolism.
• Patients struggling with digestive health issues, such as bloating, diarrhea, acid reflux, IBS, or IBD, can particularly benefit from the comprehensive analysis of their gut microbiome and metabolic profile.

iollo's test results are highly actionable, offering personalized recommendations based on each patient's unique health history and context:

• Targeted interventions may include personalized dietary and lifestyle recommendations, as well as appropriate supplementation or medication when necessary.
• For example, patients with low levels of indolepropionic acid (IPA) may be advised to increase their intake of prebiotic fibers and probiotic foods or supplements to support the growth of beneficial gut bacteria [12,13].
• Those with elevated levels of p-cresol sulfate or indoxyl sulfate may benefit from reducing their consumption of animal protein and increasing their intake of polyphenol-rich plant foods to modulate gut bacteria and reduce the production of these toxins [12,13].

Physicians can assist patients in prioritizing 2-3 key recommendations to focus on initially, based on the most significant imbalances in gut-derived metabolites and the patient's individual goals and preferences.

Regular monitoring of these biomarkers can also help track patients' progress and optimize their treatment plans over time.

‍

Conclusion

Iillo's advanced metabolomic testing provides healthcare providers with a powerful tool to assess and optimize their patients' digestive health. By understanding the key markers measured and their implications for gut function and microbiome health, physicians can develop personalized interventions that address underlying imbalances and support their patients' well-being.

Integrating iollo's testing into clinical practice can complement other functional and integrative approaches to digestive wellness, ultimately helping patients achieve optimal gut health and overall well-being.

To learn more about iollo's metabolomic testing and how it can benefit your patients, please visit www.iollo.com or contact our support team at support@iollo.com.

‍

References

[1] Jiang et al. (2022). Nutrients. 15(1):151.
[2] Noerman et al. (2021). Clin Nutr. 40(5):3250-3262.
[3] Tuomainen et al. (2018). Nutr Diabetes. 8(1):35.
[4] Liu et al. (2020). Nat Commun. 11(1):855.
[5] Melis et al. (2004). Curr Opin Clin Nutr Metab Care. 7(1):59-70.
[6] Kim & Kim (2017). Int J Mol Sci. 18(5):1051.
[7] Gryp et al. (2017). Toxins. 9(2):52.
[8] Falconi et al. (2021). Front Physiol. 12:686249.
[9] Hassan et al. (2022). Egypt J Intern Med. 34(1):1-7.
[10] Guzior & Quinn (2021). Microbiome. 9(1):1-13.
[11] Procházková et al. (2023). Gut. 72(1):180-191.
[12] Hassan et al. (2022). Egypt J Intern Med. 34(1):1-7.
[13] Bao et al. (2020). Front Immunol. 10:2981.

‍